Search

Your search keyword '"Shepherd, F.A."' showing total 54 results
Start Over Author "Shepherd, F.A." Publisher elsevier b.v.
54 results on '"Shepherd, F.A."'

1. Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohort

Author

Li, Y., Wong, M., Zhan, L., Corke, L., Brown, M.C., Cheng, S., Khan, K., Balatnaram, K., Chowdhury, M., Sabouhanian, A., Herman, J., Walia, P., Strom, E, Patel, D., García-Pardo, M., Schmid, S., Eng, L., Sacher, A.G., Leighl, N., Bradbury, P.A., Shepherd, F.A., Shultz, D., and Liu, G.

Published
2024
Full Text
View/download PDF

25. First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status: Metastatic Non-Small Cell Lung Cancer.

Author

Rizvi, N.A., Shepherd, F.A., Antonia, S.J., Brahmer, J.R., Chow, L.Q., Goldman, J., Juergens, R., Borghaei, H., Ready, N.E., Gerber, D.E., Shen, Y., Harbison, C., Chen, A.C., and Gettinger, S.

Subjects
*MONOCLONAL antibodies, *LUNG cancer treatment, *METASTASIS, *MEDICATION safety, *DRUG efficacy
Published
2014
Full Text
View/download PDF

29. 2P Single-cell profiling and integrative TCR analysis reveals tumor-mutation associated phenotypes and immune repertoire in lung adenocarcinoma.

Author

Lozano, A.X., Ghaedi, M., Azarmina, A., Sayad, A., Lien, S.C., Soleimani, S., Chung, D.C., Jacquelot, N., Waddell, T.K., Yasufuku, K., de Perrot, M., Eng, L., Shepherd, F.A., Bradbury, P.A., Leighl, N.B., Liu, G., Tsao, M-S., Pugh, T.J., Ohashi, P.S., and Sacher, A.G.

Subjects
*PHENOTYPES, *LUNGS, *ADENOCARCINOMA
Published
2024
Full Text
View/download PDF

30. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.

Author

Papadimitrakopoulou, V.A., Mok, T.S., Han, J.-Y., Ahn, M.-J., Delmonte, A., Ramalingam, S.S., Kim, S.W., Shepherd, F.A., Laskin, J., He, Y., Akamatsu, H., Theelen, W.S.M.E., Su, W.-C., John, T., Sebastian, M., Mann, H., Miranda, M., Laus, G., Rukazenkov, Y., and Wu, Y.-L.

Subjects
*EPIDERMAL growth factor receptors, *PROTEIN-tyrosine kinase inhibitors, *NON-small-cell lung carcinoma, *CANCER patients, *CANCER treatment
Abstract

In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression-free survival and improved response in patients with EGFR T790M advanced non-small-cell lung cancer (NSCLC) and progression on prior EGFR-TKI treatment. We report the final AURA3 overall survival (OS) analysis. Adult patients were randomized 2 : 1 to osimertinib (80 mg orally, once daily) or pemetrexed plus carboplatin/cisplatin (platinum–pemetrexed) intravenously, every 3 weeks (≤6 cycles). Patients could crossover to osimertinib on progression confirmed by blinded independent central review. OS and safety were secondary end points. A total of 279 patients were randomly assigned to receive osimertinib and 140 to platinum–pemetrexed (136 received treatment). At data cut-off (DCO; 15 March 2019), 188 patients (67%) receiving osimertinib versus 93 (66%) receiving platinum–pemetrexed had died. The hazard ratio (HR) for OS was 0.87 [95% confidence interval (CI) 0.67–1.12; P = 0.277]; the median OS was 26.8 months (95% CI 23.5–31.5) versus 22.5 months (95% CI 20.2–28.8) for osimertinib and platinum–pemetrexed, respectively. The estimated 24- and 36-month survival was 55% versus 43% and 37% versus 30%, respectively. After crossover adjustment, there was an HR of 0.54 (95% CI 0.18–1.6). Time to first subsequent therapy or death showed a clinically meaningful advantage toward osimertinib (HR 0.21, 95% CI 0.16–0.28; P < 0.001). At DCO, 99/136 (73%) patients in the platinum–pemetrexed arm had crossed over to osimertinib, 66/99 (67%) of whom had died. The most common adverse events possibly related to study treatment were diarrhea (32%; grade ≥3, 1%) and rash (grouped term; 32%; grade ≥3, <1%) in the osimertinib arm, versus nausea (47%; grade ≥3, 3%) in the platinum–pemetrexed arm. In patients with T790M advanced NSCLC, no statistically significant benefit in OS was observed for osimertinib versus platinum–pemetrexed, which possibly reflects the high crossover rate of patients from platinum–pemetrexed to osimertinib. ClinicalTrials.gov NCT02151981 ; https://clinicaltrials.gov/ct2/show/NCT02151981. • Median OS with osimertinib was 26.8 months versus 22.5 months with platinum–pemetrexed (HR 0.87, 95% CI 0.67–1.12; P = 0.277). • The lack of a significant survival benefit could reflect high percentage (73%) of platinum–pemetrexed to osimertinib crossover. • Analysis of OS adjusted for crossover showed an HR of 0.54 (95% CI 0.18–1.60). • Among patients receiving subsequent anticancer therapy, platinum chemotherapy was the most common after osimertinib (65%). • Grade ≥3 (possibly treatment-related) adverse events were observed less frequently with osimertinib (9% versus 34% with platinum–pemetrexed). [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

31. 512MO FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC.

Author

Planchard, D., Jänne, P.A., Cheng, Y., Lee, C.K., Laktionov, K., Yang, T-Y., Yu, Y., Kato, T., Jiang, L., Chewaskulyong, B., Lucien Geater, S., Maurel, J-M., Rojas, C., Havel, L., Shepherd, F.A., Tanaka, K., Ghiorghiu, D., Armenteros Monterroso, E., Huang, X., and Yang, J.C-H.

Subjects
*OSIMERTINIB, *NON-small-cell lung carcinoma, *CANCER chemotherapy, *SAFETY
Published
2023
Full Text
View/download PDF

32. 296P Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA.

Author

Wu, Y-L., Tsuboi, M., Grohe, C., John, T., Majem Tarruella, M., Wang, J., Kato, T., Goldman, J.W., Kim, S-W., Yu, C-J., Vinh Vu, H., Mukhametshina, G., Akewanlop, C., de Marinis, F., Shepherd, F.A., Urban, D., Stachowiak, M., Bolanos, A., Huang, X., and Herbst, R.S.

Subjects
*NON-small-cell lung carcinoma, *OSIMERTINIB
Published
2022
Full Text
View/download PDF

33. LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA.

Author

Tsuboi, M., Wu, Y-L., Grohe, C., John, T., Tarruella, M. Majem, Wang, J., Kato, T., Goldman, J.W., Kim, S-W., Yu, C-J., Vu, H. Vinh, Mukhametshina, G., Akewanlop, C., de Marinis, F., Shepherd, F.A., Urban, D., Stachowiak, M., Bolanos, A.L., Huang, X., and Herbst, R.S.

Subjects
*NON-small-cell lung carcinoma, *OSIMERTINIB
Published
2022
Full Text
View/download PDF

34. 1202TiP Evolution of the tumor immune microenvironment in hepatocellular carcinoma (HCC) and non-squamous non-small cell lung cancer (NSCLC) with liver metastases treated with atezolizumab and bevacizumab (INTEGRATE).

Author

Sacher, A., Lau, S., Allen, M., Corke, L., Makarem, M., Chen, E., Jang, R.W-J., Elimova, E., Grant, R., Shepherd, F.A., Bradbury, P., Eng, L., Rogalla, P., Liu, G., Tsao, M-S., Leighl, N., Garonce-Hediger, R., Wang, B., Ohashi, P., and Knox, J.

Subjects
*NON-small-cell lung carcinoma, *HEPATOCELLULAR carcinoma, *BEVACIZUMAB, *TUMOR microenvironment, *ATEZOLIZUMAB
Published
2022
Full Text
View/download PDF

36. 1144P Clinical outcomes of NSCLC patients (pts) who had brain-only metastasis at time of stage IV diagnosis, by presence versus absence of EGFR/ALK mutations.

Author

Schmid, S., Zhan, L.J., Garcia, M., Cheng, S., Khan, K., Chowdhury, M.T., Sabouhanian, A., Herman, J., Walia, P., Strom, E., Brown, M.C., Patel, D., Xu, W., Shepherd, F.A., Sacher, A., Leighl, N., Bradbury, P., Shultz, D., and Liu, G.

Subjects
*EPIDERMAL growth factor receptors, *TREATMENT effectiveness, *METASTASIS, *DIAGNOSIS
Published
2022
Full Text
View/download PDF

38. 1809P Evaluation of KRAS mutation subtype on survival in patients with metastatic non-small cell lung cancer receiving immunotherapy.

Author

Barron, C.C., Kuang, S., Makarem, M., Elliott, M.J., Sharma, K., Lee, J., Schmid, S., Rabinovitch, A., Bradbury, P., Liu, G., Shepherd, F.A., Tsao, M.S., Leighl, N., Rose, A., Pezo, R., Doherty, M., Cheng, S., Lau, S.C., and Sacher, A.

Subjects
*NON-small-cell lung carcinoma, *IMMUNOTHERAPY, *METASTATIC breast cancer, *EPIDERMAL growth factor receptors, *METASTASIS
Published
2021
Full Text
View/download PDF

40. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.

Author

Laurie, S.A., Solomon, B.J., Seymour, L., Ellis, P.M., Goss, G.D., Shepherd, F.A., Boyer, M.J., Arnold, A.M., Clingan, P., Laberge, F., Fenton, D., Hirsh, V., Zukin, M., Stockler, M.R., Lee, C.W., Chen, E.X., Montenegro, A., Ding, K., and Bradbury, P.A.

Subjects
*ANTINEOPLASTIC agents, *CANCER chemotherapy, *CLINICAL trials, *CONFIDENCE intervals, *LUNG cancer, *PROBABILITY theory, *SURVIVAL, *DESCRIPTIVE statistics
Abstract

Abstract: Introduction: This randomised double-blind placebo-controlled study evaluated the addition of cediranib, an inhibitor of vascular endothelial growth factor receptors 1–3, to standard carboplatin/paclitaxel chemotherapy in advanced non-small cell lung cancer. Methods: Eligible patients received paclitaxel (200mg/m2) and carboplatin (area under the concentration time curve 6) intravenously every 3weeks. Daily oral cediranib/placebo 20mg was commenced day 1 of cycle 1 and continued as monotherapy after completion of 4–6 cycles of chemotherapy. The primary end-point of the study was overall survival (OS). The trial would continue to full accrual if an interim analysis (IA) for progression-free survival (PFS), performed after 170 events of progression or death in the first 260 randomised patients, revealed a hazard ratio (HR) for PFS of ⩽0.70. Results: The trial was halted for futility at the IA (HR for PFS 0.89, 95% confidence interval [CI] 0.66–1.20, p =0.45). A final analysis was performed on all 306 enrolled patients. The addition of cediranib increased response rate ([RR] 52% versus 34%, p =0.001) but did not significantly improve PFS (HR 0.91, 95% CI 0.71–1.18, p =0.49) or OS (HR 0.94, 95% CI 0.69–1.30, p =0.72). Cediranib patients had more grade 3 hypertension, diarrhoea and anorexia. Conclusions: The addition of cediranib 20mg daily to carboplatin/paclitaxel chemotherapy increased RR and toxicity, but not survival. [Copyright &y& Elsevier]

Published
2014
Full Text
View/download PDF

41. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib.

Author

Hilton, J.F., Tu, D., Seymour, L., Shepherd, F.A., and Bradbury, P.A.

Subjects
*GASTRIC acid, *PROTEIN-tyrosine kinase inhibitors, *TUMOR suppressor proteins, *EPIDERMAL growth factor receptors, *BIOAVAILABILITY, *HYDROGEN ions, *MEDICAL databases
Abstract

Abstract: Objectives: As the bioavailability of erlotinib is dependent on gastric pH, an increase in gastric pH via the concurrent use of gastric acid suppressive medications (AS) may reduce its bioavailability and efficacy. We retrospectively analyzed the BR.21 trial database to pragmatically evaluate the impact of AS use on the median plasma drug levels of erlotinib, adverse events and outcome of participants. Methods: Monthly median plasma levels of erlotinib were compared between participants utilizing AS and those who did not using a Wilcoxon test. Interaction p-value for AS users and AS non-users was performed using a multivariate Cox model with a time-dependent covariate for AS use. Grade 2 adverse events were compared using Fisher's Exact Test. Results: The median plasma erlotinib level was not significantly different between AS users and AS non-users, and AS use did not appear to incur a negative impact on PFS or OS (Interaction p-values: PFS p =0.16; OS p =0.81). AS users receiving erlotinib had a similar frequency of rash (50.5% vs. 42.0%, p =0.08) and a statistically higher rate of diarrhea (27.9% vs. 15.6%, p =0.001) compared to AS non-users. In addition, AS users had higher rates of infections (erlotinib arm: 33.7% vs. 20.0%, p <0.0001; placebo arm: 22.7% vs. 10.8%, p =0.02). Conclusion: This retrospective analysis found that the co-administration of AS and erlotinib did not appear to have a significant impact on the median plasma drug levels or outcome. [Copyright &y& Elsevier]

Published
2013
Full Text
View/download PDF

43. Validation of treatment induced specific adverse effect as a predictor of treatment benefit: A case study of NCIC CTG BR21

Author

Ding, K., Pater, J., Whitehead, M., Seymour, L., and Shepherd, F.A.

Subjects
*DRUG efficacy, *DRUG side effects, *CASE studies, *CLINICAL trials
Abstract

Abstract: The target of novel signal transduction inhibitors may be present on normal as well as tumor cells, resulting in mechanistic adverse effects (AE) in addition to antitumor activity. As those AEs lie in the causal pathway that patients respond to the drug, may thus serve as an indicator of benefit from the drug. In this paper, we discuss issues in validating drug related AEs as predictive markers of overall survival benefit. Based on our proposed approach, we showed that erlotinib induced skin rash appears to predict a survival benefit. [Copyright &y& Elsevier]

Published
2008
Full Text
View/download PDF

44. Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: The JBR.10 trial experience

Author

Gauthier, I., Ding, K., Winton, T., Shepherd, F.A., Livingston, R., Johnson, D.H., Rigas, J.R., Whitehead, M., Graham, B., and Seymour, L.

Subjects
*HEMOGLOBINS, *ANEMIA, *ADJUVANT treatment of cancer, *LUNG cancer
Abstract

Summary: Background: Cisplatin-induced anemia may correlate with adverse events, poor quality of life (QoL), decreased adjuvant chemotherapy (ACT) dose intensity, shorter relapse-free survival (RFS) or overall survival (OS). Methods: The JBR.10 trial demonstrated significantly longer survival with adjuvant cisplatin and vinorelbine (n =242) compared to observation (n =240) in patients with resected NSCLC [Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352(25):2640–2]. This exploratory analysis evaluates the predictive value of baseline (in all patients) and during-treatment (in ACT arm only) hemoglobin (Hb) levels on OS and RFS when adjusted for prognostic factors. Baseline (in all patients) and during treatment (in ACT arm only) Hb levels were also correlated with adverse events, QoL, morbidity and ACT dose intensity. Results: Baseline Hb did not predict RFS or OS. However, there was a trend to shorter OS (p =0.1) when baseline Hb was <120g/L. Lower baseline Hb predicted increased hospitalization (p =0.04) and worse QoL (SOB item, p =0.03) but had no impact on adverse events or dose intensity. There was a trend to longer RFS (p =0.08) in patients with lower nadir during-treatment Hb and to longer OS (p =0.06) and RFS (p =0.08) in patients with maximum during-treatment Hb drop >30% that was not maintained when ACT dose intensity was included in the model. Maximum during-treatment Hb drop >30% correlated with increased lethargy (p =0.003) and worse QoL (fatigue item, p =0.07). Conclusions: Lower baseline and during-treatment Hb levels seem associated with poorer QoL, fatigue and increased hospitalization. There is a trend for shorter OS in patients with lower baseline Hb levels. [Copyright &y& Elsevier]

Published
2007
Full Text
View/download PDF

45. Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer

Author

Leighl, Natasha B., Goss, G.D., Lopez, P.G., Burkes, R.L., Dancey, J.E., Rahim, Y.H., Rudinskas, L.C., Pouliot, J.F., Rodgers, A., Pond, G.R., and Shepherd, F.A.

Subjects
*CLINICAL trials, *COMBINATION drug therapy, *CANCER treatment, *SMALL cell lung cancer
Abstract

Summary: Background: Despite chemotherapy and radiotherapy for small cell lung cancer (SCLC), most patients die within 2 years. Response rates for second-line chemotherapy are 15–25%, with a median survival of 5 months. Caelyx, a pegylated liposomal formulation of doxorubicin, may be better tolerated and has activity in SCLC. Patients and methods: Thirty-two patients were enrolled in a phase II study of intravenous Caelyx (35mg/m2), cyclophosphamide (750mg/m2) and vincristine (1.2mg/m2) every 21 days as second-line therapy in SCLC for up to six cycles. Results: Thirty patients were evaluable for response, with a response rate of 10%. Another two had an unconfirmed response. Stable disease (SD) for ≥2 cycles was seen in an additional 53%. Grade 3 or 4 non-hematologic toxicity was seen in 17 (55%) patients (26 [22%] cycles) and included fatigue, mucositis, plantar-palmar erythrodysesthesia, rash and neuropathy. Twelve patients required transfusions. All patients on study have now expired, with a median survival of 28 weeks (7 months). For patients with SD or partial response, median time to progression was 15 weeks. Conclusion: The combination of Caelyx, cyclophosphamide and vincristine, despite cyclophosphamide and Caelyx dose reductions, has modest activity in relapsed SCLC with acceptable toxicity. [Copyright &y& Elsevier]

Published
2006
Full Text
View/download PDF

46. 531P Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Preliminary results of the investigator initiated phase II BEAVER trial.

Author

Rose, A., Ayodele, O., Genta, S., Muniz, T. Pimentel, Kelly, D.C., Hodgson, K., King, I., Stockley, T., Pugh, T., Kamil, Z. Saeed, Butler, M.O., Shepherd, F.A., Bedard, P., Leighl, N., Razak, A.R. Abdul, Hansen, A.R., Saibil, S., Cescon, D.W., Siu, L.L., and Spreafico, A.

Subjects
*BRAF genes, *BEAVERS, *THERAPEUTICS, *TUMORS
Published
2021
Full Text
View/download PDF

47. 356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence.

Author

Tsuboi, M., Wu, Y-L., He, J., John, T., Grohe, C., Majem, M., Goldman, J.W., Laktionov, K., Kim, S-W., Kato, T., Vu, H.V., Akewanlop, C., Yu, C-J., de Marinis, F., Domine, M., Shepherd, F.A., Yan, C., Atasoy, A., and Herbst, R.

Subjects
*ADJUVANT treatment of cancer, *OSIMERTINIB, *NON-small-cell lung carcinoma
Published
2020
Full Text
View/download PDF

48. LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence.

Author

Tsuboi, M., Wu, Y-L., He, J., John, T., Grohe, C., Majem, M., Goldman, J.W., Laktionov, K., Kim, S-W., Kato, T., Vu, H.V., Akewanlop, C., Yu, C-J., de Marinis, F., Domine, M., Shepherd, F.A., Yan, C., Atasoy, A., and Herbst, R.

Subjects
*CENTRAL nervous system, *EPIDERMAL growth factor receptors, *DISEASE relapse, *OSIMERTINIB, *NON-small-cell lung carcinoma
Published
2020
Full Text
View/download PDF

49. Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC): Metastatic Non-Small Cell Lung Cancer.

Author

Antonia, S.J., Brahmer, J.R., Gettinger, S., Chow, L.Q., Juergens, R., Shepherd, F.A., Laurie, S.A., Gerber, D.E., Goldman, J., Shen, Y., Harbison, C., Chen, A.C., Borghaei, H., and Rizvi, N.A.

Subjects
*CANCER chemotherapy, *LUNG cancer, *METASTASIS, *MONOCLONAL antibodies, *FOLLOW-up studies (Medicine), *MEDICAL statistics
Published
2014
Full Text
View/download PDF

50. Adjuvant Erlotinib (E) Versus Placebo (P) for Completely Resected Stage IB-IIIA EGFR-Positive (IHC/FISH) Non-Small Cell Lung Cancer (NSCLC): RADIANT Results: Locally Advanced Non-Small Cell Lung Cancer.

Author

Altorki, N.K., O'brien, M.E.R., Eberhardt, W.E.E., Richardson, F.C., Wang, J., Foley, M.A., Horan, J.D., Shepherd, F.A., and Kelly, K.

Subjects
*ERLOTINIB, *LUNG cancer, *EPIDERMAL growth factor receptors, *PLACEBOS, *ADJUVANT treatment of cancer, *ANTINEOPLASTIC agents
Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results